Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydroxychloroquine in COVID-19 (PREVENT)
NCT04371926Withdrawn
- Sponsor
- Texas Cardiac Arrhythmia Research Foundation
- Start
- Jun 2020
- Primary completion
- Jun 2021
- Modality
- Small Molecules
01
Overview
Randomised, open-label trial of hydroxychloroquine in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Texas Cardiac Arrhythmia Research Foundation. Primary endpoints: Time to reach normal body temperature at 1 month and Development of COVID-19 symptoms during HCQ preventive therapy in staff at 1 month. Planned start Jun 2020; status: withdrawn.
02
Drugs
hydroxychloroquine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04371926.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04371926.